Abstract
Objectives: Niacin showed no benefit on cardiovascular events in 2 outcome trials in high-risk subjects. However, this broad spectrum lipid-modulating agent remains clinically relevant in patients who do not reach goals despite statin therapy; indeed, such patients typically display altered postprandial lipoprotein metabolism. While the effect of niacin on fasting lipids is well established, its impact on postprandial lipoprotein metabolism remains indeterminate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.